Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

PRME


Fundamental

Company: Prime Medicine Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -1.37
Insider Own: 47.66%
Shs Outstand: 180.51M
Perf Week: 3.31%
Market Cap: 619.29M
Forward P/E: -
EPS next Y: -0.85
Insider Trans: 0.00%
Shs Float: 94.50M
Perf Month: -10.44%
Enterprise Value: 558.04M
PEG: -
EPS next Q: -0.25
Inst Own: 41.34%
Short Float: 31.70%
Perf Quarter: -12.50%
Income: -201.14M
P/S: 133.76
EPS this Y: 30.16%
Inst Trans: 5.52%
Short Ratio: 10.60
Perf Half Y: -46.82%
Sales: 4.63M
P/B: 5.12
EPS next Y Percentage: 9.74%
ROA: -36.35%
Short Interest: 29.96M
Perf YTD: -1.15%
Book/sh: 0.67
P/C: 3.49
EPS next 5Y: 15.47%
ROE: -146.81%
52W High: 6.94 -50.58%
Perf Year: 193.16%
Cash/sh: 0.98
P/FCF: -
EPS past 3/5Y: 2.55% -91.28%
ROIC: -87.77%
52W Low: 1.11 209.01%
Perf 3Y: -72.11%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -2.32%
Gross Margin: -58.05%
Volatility W: 6.51%
Volatility M: 7.08%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 120.53
EPS Y/Y TTM: 19.04%
Oper. Margin: -4498.06%
ATR (14): 0.27
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 4.84
Sales Y/Y TTM: 55.28%
Profit Margin: -4342.44%
RSI (14): 45.46
Recom: 1.55
Dividend Gr. 3/5Y: - -
Current Ratio: 4.84
EPS Q/Q: 28.39%
SMA20: -2.11%
Beta: 2.63
Target Price: 7.16
Payout: -
Debt/Eq: 0.96
Sales Q/Q: -61.61%
SMA50: -6.38%
Rel Volume: 0.60
Prev Close: 3.51
Employees: 146
LT Debt/Eq: 0.90
Earnings: Mar 03 BMO
SMA200: -15.38%
Avg Volume: 2.83M
Price: 3.43
IPO: Oct 20, 2022
Option/Short: Yes / Yes
EPS/Sales Surpr.: 12.49% -34.60%
Trades:
Volume: 1,684,567
Change: -2.28%

Technical:


Latest News:

Citigroup Upgrades Prime Medicine (PRME) - Nasdaq very bullish
PRME

Summary: Citigroup upgraded their outlook for Prime Medicine from Neutral to Buy with an analyst price forecast suggesting 114.11% upside. Various funds and institutions have reported positions in Prime Medicine, totaling 70,064K shares, with a bullish outlook indicated by the put/call ratio of 0.12.

Full article
2024-05-17T22:16:55Z